Department of Urology, University of Michigan, Ann Arbor, Michigan.
Division of Infectious Disease, University of Michigan, Ann Arbor, Michigan.
J Urol. 2015 Aug;194(2):403-9. doi: 10.1016/j.juro.2015.03.126. Epub 2015 Apr 17.
Recent data suggest that increasing rates of hospitalization after prostate biopsy are mainly due to infections from fluoroquinolone-resistant bacteria. We report the initial results of a statewide quality improvement intervention aimed at reducing infection related hospitalizations after transrectal prostate biopsy.
From March 2012 through May 2014 data on patient demographics, comorbidities, prophylactic antibiotics and post-biopsy complications were prospectively entered into an electronic registry by trained abstractors in 30 practices participating in the MUSIC. During this period each practice implemented one or both of the interventions aimed at addressing fluoroquinolone resistance, namely 1) use of rectal swab culture directed antibiotics or 2) augmented antibiotic prophylaxis with a second agent in addition to standard fluoroquinolone therapy. We identified all patients with an infection related hospitalization within 30 days after biopsy and validated these events with claims data for a subset of patients. We then compared the frequency of infection related hospitalizations before (5,028 biopsies) and after (4,087 biopsies) implementation of the quality improvement intervention.
Overall the proportion of patients with infection related hospitalizations after prostate biopsy decreased by 53% from before to after implementation of the quality improvement intervention (1.19% before vs 0.56% after, p=0.002). Among post-implementation biopsies the rates of hospitalization were similar for patients receiving culture directed (0.47%) vs augmented (0.57%) prophylaxis. At a practice level the relative change in hospitalization rates varied from a 7.4% decrease to a 3.0% increase. Fourteen practices had no post-implementation hospitalizations.
A statewide intervention aimed at addressing fluoroquinolone resistance reduced post-prostate biopsy infection related hospitalizations in Michigan by 53%.
最近的数据表明,前列腺活检后住院率的上升主要是由于耐氟喹诺酮类细菌感染所致。我们报告了一项全州范围的质量改进干预措施的初步结果,该措施旨在减少经直肠前列腺活检后与感染相关的住院治疗。
从 2012 年 3 月到 2014 年 5 月,通过训练有素的摘要员在 30 家参与 MUSIC 的实践中,前瞻性地将患者人口统计学、合并症、预防性抗生素和活检后并发症的数据录入电子登记册。在此期间,每家实践都实施了一项或两项干预措施,以解决氟喹诺酮类药物耐药问题,即 1)使用直肠拭子培养指导抗生素,或 2)在标准氟喹诺酮治疗基础上加用第二种药物来增强抗生素预防。我们确定了所有在活检后 30 天内发生与感染相关的住院治疗的患者,并通过对部分患者的索赔数据对这些事件进行了验证。然后,我们比较了质量改进干预实施前后(5028 次活检)与感染相关的住院治疗频率。
总体而言,前列腺活检后与感染相关的住院治疗的比例从质量改进干预实施前的 1.19%下降到实施后的 0.56%(p=0.002),下降了 53%。在实施后活检中,接受培养指导(0.47%)和增强(0.57%)预防的患者的住院率相似。在实践层面,住院率的相对变化从下降 7.4%到上升 3.0%不等。有 14 家实践没有实施后住院治疗。
一项旨在解决氟喹诺酮类耐药问题的全州范围的干预措施,使密歇根州经直肠前列腺活检后与感染相关的住院治疗减少了 53%。